Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 901–1,000 of 15,747
Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy
Vincent, M. P., Navidzadeh, J. O., Bobbala, S. K. R., & Scott, E. A. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.006 · Cited by 126
Montero, C. G., Fraile‐Μartinez, O., Bravo, C., Torres‐Carranza, D., Sánchez‐Trujillo, L., Gomez-Lahoz, A. M., Guijarro, L. G., García‐Honduvilla, N., Asúnsolo, Á., Buján, J., et al. (2021) · Vaccines · doi:10.3390/vaccines9050433 · Cited by 117
Regulating trained immunity with nanomedicine
van Leent, M. M. T., Priem, B., Schrijver, D. P., de Dreu, A., Hofstraat, S. R. J., Zwolsman, R. C., Beldman, T. J., Netea, M. G., & Mulder, W. J. M. (2022) · Nature Reviews Materials · doi:10.1038/s41578-021-00413-w · Cited by 122
Thatiparthi, A., Martin, A., Liu, J., Egeberg, A., & Wu, J. J. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00603-w · Cited by 122
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Chiu, H.-P., Stevens, C. S., Vilardo, A. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24909-9 · Cited by 144
Renoud, L., Khouri, C., Revol, B., Lepelley, M., Perez, J., Roustit, M., & Cracowski, J. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.2219 · Cited by 122
Self-citationSARS-CoV-2 vaccines: a triumph of science and collaboration
Golob, J. L., Lugogo, N. L., Lauring, A. S., & Lok, A. S.-F. (2021) · JCI Insight · doi:10.1172/jci.insight.149187 · Cited by 123
Ranzani, O. T., Hitchings, M. D. T., de Melo, R. L., de França, G. V. A., Fernandes, C. D. F. R., Lind, M. L., Torres, M. S. S., Tsuha, D. H., David, L. C. S., Said, R. F. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33169-0 · Cited by 111
“127 Interval between symptoms onset and RTPCR testing, median (p25-p75), days 3 [2, 4] 3 [1, 4] 0.”
BackgroundInfluentialImmune thrombocytopenia in a 22 ‐year‐old post C ovid‐ 19 vaccine
Tarawneh, O. H., & Tarawneh, H. S. (2021) · American Journal of Hematology · doi:10.1002/ajh.26106 · Cited by 121
O’Brien, M. P., Forleo-Neto, E., Sarkar, N., Isa, F., Hou, P., Chan, K.-C., Musser, B. J., Bar, K. J., Barnabas, R. V., Barouch, D. H., et al. (2022) · JAMA · doi:10.1001/jama.2021.24939 · Cited by 135
van Gils, M. J., Lavell, A. H. A., van der Straten, K., Appelman, B., Bontjer, I., Poniman, M., Burger, J. A., Oomen, M., Bouhuijs, J. H., van Vught, L. A., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1003991 · Cited by 115
Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals
Milman, O., Yelin, I., Aharony, N., Katz, R., Herzel, E., Ben‐Tov, A., Kuint, J., Gazit, S., Chodick, G., Patalon, T., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01407-5 · Cited by 115
Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
Regev-Yochay, G., Amit, S., Bergwerk, M., Lipsitch, M., Leshem, E., Kahn, R., Lustig, Y., Cohen, C., Doolman, R., Ziv, A., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100150 · Cited by 111
“The BNT162b2 COVID-19 vaccine was shown to be highly efficacious (95%) in preventing clinical COVID-19 infection [4] and highly effective following the first and second doses [5,6].”
BackgroundResultReview of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD
Carr, E. J., Kronbichler, A., Graham-Brown, M. P. M., Abra, G. E., Argyropoulos, C., Harper, L., Lerma, E. V., Suri, R. S., Topf, J. M., Willicombe, M. K., et al. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.06.027 · Cited by 129
“However, the efficacy of vaccination in this population remains uncertain because these patients were not included in the original efficacy trials.(39,40) Several small studies investigating the role of the COVID-19 vaccine in dialysis patients have been reported recently and are summarized in Table 2.”
COVID-19 vaccine breakthrough infections
Gupta, R. K., & Topol, E. J. (2021) · Science · doi:10.1126/science.abl8487 · Cited by 114
A Prospective Cohort Study of COVID-19 Vaccination, SARS-CoV-2 Infection, and Fertility
Wesselink, A. K., Hatch, E. E., Rothman, K. J., Wang, T. R., Willis, M. D., Yland, J. J., Crowe, H. M., Geller, R. J., Willis, S. K., Perkins, R. B., et al. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac011 · Cited by 120
Chemaitelly, H. S., Ayoub, H. H., Tang, P., Coyle, P. V., Yassine, H. M., Thani, A. A. A., Al-Khatib, H. A., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00058-0 · Cited by 117
Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2
Granados-Riveron, J. T., & Aquino-Jarquin, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111953 · Cited by 111
Liu, Z., Zhou, J., Xu, W., Deng, W., Wang, Y., Wang, M., Wang, Q., Hsieh, M. K., Dong, J., Wang, X., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00612-2 · Cited by 118
Zhu, Y., Ma, J., Shen, R., Lin, J., Li, S., Lu, X., Stelzel, J. L., Kong, J., Cheng, L., Vuong, I., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01131-0 · Cited by 126
Xin, T., Li, C., Zhou, C., Zhao, Y., Hu, Z., & Wu, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.809754 · Cited by 121
“Especially, lipid-based nanoparticles have recently been successfully used to deliver SARS-CoV-2 mRNA vaccines (106).”
MethodGresham, R. C. H., Bahney, C. S., & Leach, J. K. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.12.012 · Cited by 139
Marfella, R., D’Onofrio, N., Sardu, C., Scisciola, L., Maggi, P., Coppola, N., Romano, C. P., Messina, V., Turriziani, F., Siniscalchi, M., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14547 · Cited by 119
“Third, as previously reported, we evaluated the outcomes during the period of higher immunological responses for each SARS-COV-2 vaccine type.(18) As reported in Supplementary Figure 2, there were no differences in the immunological responses among the different SARS-COV-2 vaccines studied.”
ResultPuig‐Domingo, M., Marazuela, M., Yıldız, B. O., & Giustina, A. (2021) · Endocrine · doi:10.1007/s12020-021-02734-w · Cited by 120
“Patients with stable diabetes and obesity were enrolled in these trials and similar efficacy and safety were reported as compared to healthy subjects [136, 137].”
BackgroundTada, T., Zhou, H., Samanovic, M., et al. (2021) · bioRxiv · doi:10.1101/2021.07.19.452771 · Cited by 97
Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19 variants
Sah, P., VILCHES, T. N., Moghadas, S. M., Fitzpatrick, M. C., Singer, B. H., Hotez, P. J., & Galvani, A. P. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100865 · Cited by 112
“In an additional scenario analysis, we considered Pfizer-BioNTech vaccines with an interval of 21 days as tested in clinical trials [37].”
Gadani, S. P., Reyes-Mantilla, M. I., Jank, L., Harris, S., Douglas, M., Smith, M. D., Calabresi, P. A., Mowry, E. M., Fitzgerald, K. C., & Bhargava, P. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103636 · Cited by 104
“The introduction of highly effective vaccines, such as the SARSCoV-2 mRNA vaccines produced by Pfizer and Moderna, provides an effective intervention to reduce the risk and severity of COVID-19 infection [4,5].”
InfluentialMyocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far?
Das, B. B., Moskowitz, W. B., Taylor, M., & Palmer, A. (2021) · Children · doi:10.3390/children8070607 · Cited by 121
“; Cambridge, MA, USA)) demonstrated excellent safety and clinical efficacy profiles in clinical trials in adults in less than one year from the identification of the virus which is unprecedented in the history of vaccinology [1,2].”
BackgroundCOVID-19 Vaccine Booster: To Boost or Not to Boost
Shekhar, R., Garg, I., Pal, S., Kottewar, S., & Sheikh, A. B. (2021) · Infectious Disease Reports · doi:10.3390/idr13040084 · Cited by 112
Song, Q., Bates, B. A., Shao, Y. R., Hsu, F., Liu, F., Madhira, V., Mitra, A., Bergquist, T., Kavuluru, R., Li, X., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02419 · Cited by 114
Disanto, G., Sacco, R., Bernasconi, E., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3609 · Cited by 109
From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape
Chakraborty, C., Sharma, A. R., Bhattacharya, M., & Lee, S.-S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679344 · Cited by 109
Lundberg, L., Leach, S., Xu, Y., Martikainen, J., Santosa, A., Gisslén, M., Li, H., Nyberg, F., & Bygdell, M. (2023) · BMJ · doi:10.1136/bmj-2023-076990 · Cited by 121
Tenforde, M. W., Patel, M. M., Ginde, A. A., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., Gaglani, M., McNeal, T., et al. (2021) · medRxiv · doi:10.1101/2021.07.08.21259776 · Cited by 108
“[3, 4] However, these clinical trials had few cases of hospitalized Covid-19, and limited power to assess efficacy among persons with underlying illnesses who are at high risk for severe Covid-19.”
BackgroundResultInfluentialFusco, M. D., Lin, J., Vaghela, S., Lingohr-Smith, M., Nguyen, J. L., Sforzolini, T. S., Judy, J., Cane, A. D., & Moran, M. M. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2035222 · Cited by 116
“Such findings from real-world studies are generally consistent with the efficacy results of the randomized clinical trials (RCTs) of these vaccines [4-7].”
MethodResultThe real-life impact of vaccination on COVID-19 mortality in Europe and Israel
Jabłońska, K., Aballéa, S., & Toumi, M. (2021) · Public Health · doi:10.1016/j.puhe.2021.07.037 · Cited by 116
“Results of clinical trials on vaccine efficacy revealed that Pfizer-BioNTech had 95% efficacy at preventing symptomatic COVID-19 infection in people without prior infection.(25) 94.”
BackgroundAddressing Vaccine Inequity — Covid-19 Vaccines as a Global Public Good
Hunter, D. J., Karim, S. S. A., Baden, L. R., Farrar, J., Hamel, M. B., Longo, D. L., Morrissey, S., & Rubin, E. J. (2022) · New England Journal of Medicine · doi:10.1056/nejme2202547 · Cited by 110
Tse, S.-W., McKinney, K., Walker, W., Nguyen, M., Iacovelli, J., Small, C., Hopson, K., Zaks, T., & Huang, E. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.03.002 · Cited by 108
Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers
Yin, D., Zhong, Y., Ling, S., Lu, S., Wang, X., Jiang, Z., Wang, J., Dai, Y., Tian, X., Huang, Q., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01208-4 · Cited by 127
“The success of the Moderna (mRNA-1273) and Pfizer/BioNTech (BNT162b2) vaccines against coronavirus disease 2019 (COVID-19) dramatically boosted the development of messenger RNA vaccines 10–13 .”
Karaba, A. H., Zhu, X., Liang, T., Wang, K., Rittenhouse, A. G., Akinde, O., Eby, Y. J., Ruff, J. E., Blankson, J. N., Abedon, A. T., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16933 · Cited by 116
Pape, K. A., Dileepan, T., Kabage, A. J., Kozysa, D., Batres, R., Evert, C., Matson, M., Lopez, S., Krueger, P. D., Graiziger, C. T., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109823 · Cited by 112
“mRNA vaccines encoding the SARS-CoV-2 spike protein potently induce antibodies, some capable of neutralizing the virus, and afford protective immunity from infection (Goel et al., 2021; Pascolo, 2021; Polack et al., 2020; Widge et al., 2021).”
InfluentialCOVID-19 Vaccine Hesitancy among French People Living with HIV
Vallée, A., Fourn, E., Majerholc, C., Touche, P., & Zucman, D. (2021) · Vaccines · doi:10.3390/vaccines9040302 · Cited by 119
Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans
Klasse, P. J., Nixon, D. F., & Moore, J. P. (2021) · Science Advances · doi:10.1126/sciadv.abe8065 · Cited by 107
Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar
(2021) · doi:10.1101/2021.08.25.21262584 · Cited by 831
Bravo, L., Smolenov, I., Han, H. H., Li, P., Hosain, R., Rockhold, F., Clemens, S. A. C., Roa, C., Borja-Tabora, C., Quinsaat, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00055-1 · Cited by 106
Self-citationSARS-CoV-2 vaccine uptake in a multi-ethnic UK healthcare workforce: A cross-sectional study
Martin, C., Marshall, C., Patel, P., Goss, C., Jenkins, D. R., Ellwood, C. N., Barton, L. M., Price, A., Brunskill, N. J., Khunti, K., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003823 · Cited by 110
“In recent months, thanks to an unprecedented global research effort, a number of vaccines against SARS-CoV-2 have been developed and approved [2,3], and it is hoped that mass vaccination programmes will aid in slowing transmission of the virus as well as reducing hospitalisation and death from COVID-19.”
BackgroundMethodGender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine
Green, M. S., Peer, V., Magid, A., HaGani, N., Anis, E., & Nitzan, D. (2022) · Vaccines · doi:10.3390/vaccines10020233 · Cited by 118
“For example, in the report on the Pfizer vaccine, the safety profile of the vaccine was described as “short-term, mild-to-moderate pain at the injection site, fatigue, and headache, the incidence of serious adverse events as low and similar in the vaccine and placebo groups, and safety over a median of 2 months was si…”
BackgroundmRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond
Sentí, M. E., del Valle, L. G., & Schiffelers, R. M. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115190 · Cited by 137
Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions
Abulsoud, A. I., El‐Husseiny, H. M., El-Husseiny, A. A., El‐Mahdy, H. A., Ismail, A., Elkhawaga, S. Y., Khidr, E. G., Fathi, D., Mady, E. A., Najda, A., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113977 · Cited by 116
Recent developments in the immunopathology of COVID ‐19
Zhang, H., Sun, Y., Wang, Y., Yazıcı, D., Azkur, D., Öğülür, İ., Azkur, A. K., Yang, Z., Chen, X., Zhang, A., et al. (2022) · Allergy · doi:10.1111/all.15593 · Cited by 125
Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V., Frankland, T. B., Ackerson, B. K., Takhar, H. S., Ogun, O. A., Simmons, S. R., Zamparo, J. M., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100198 · Cited by 108
Engineering synthetic RNA devices for cell control
Dykstra, P. B., Kaplan, M., & Smolke, C. D. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00436-7 · Cited by 137
Current Developments and Challenges of mRNA Vaccines
Chen, J., Chen, J., & Xu, Q. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110220-031722 · Cited by 115
The potential neurological effect of the COVID‐19 vaccines: A review
Lu, L., Xiong, W., Mu, J., Zhang, Q., Zhang, H., Zou, L., Li, W., He, L., Sander, J. W. A. S., & Zhou, D. (2021) · Acta Neurologica Scandinavica · doi:10.1111/ane.13417 · Cited by 111
Brockman, M. A., Mwimanzi, F. M., Lapointe, H. R., Sang, Y., Agafitei, O., Cheung, P. K., Ennis, S., Ng, K., Basra, S., Lim, L. Y., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab592 · Cited by 111
“Both vaccines provided > 94% protection against moderate or severe COVID-19 in clinical trials after 2 doses [6, 7] and population-level reductions in COVID-19 were observed following initial vaccine rollouts, but ongoing outbreaks in long-term care facilities underscore the continuing vulnerability of older adults to…”
Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients
Vijenthira, A., Gong, I. Y., Betschel, S., Cheung, M. C., & Hicks, L. K. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004629 · Cited by 123
The COVID-19 pandemic: viral variants and vaccine efficacy
Ciotti, M., Ciccozzi, M., Pieri, M., & Bernardini, S. (2021) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2021.1979462 · Cited by 118
Bell’s palsy following COVID-19 vaccination
Colella, G., Orlandi, M., & Cirillo, N. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10462-4 · Cited by 105
Callaghan, C. J., Mumford, L. L., Curtis, R. M. K., Williams, S. V., Whitaker, H., Andrews, N. J., Bernal, J. L., Ushiro‐Lumb, I., Pettigrew, G. J., Thorburn, D., et al. (2022) · Transplantation · doi:10.1097/tp.0000000000004059 · Cited by 107
Fröberg, J., Gillard, J., Philipsen, R. L. A., Lanke, K. H. W., Rust, J., van Tuijl, D., Teelen, K., Bousema, T., Simonetti, E. R., Jongh, C. E. V. D. G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25949-x · Cited by 113
Chu, L., Montefiori, D., Huang, W., Nestorova, B., Chang, Y., Carfi, A., Edwards, D. K., Oestreicher, J., Legault, H., Girard, B., et al. (2021) · doi:10.1101/2021.09.29.21264089 · Cited by 105
COVID-19: Challenges of Viral Variants
Jacobs, J. L., Haidar, G., & Mellors, J. W. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-020956 · Cited by 118
Current landscape of mRNA technologies and delivery systems for new modality therapeutics
Lu, R., Hsu, H.-E., Perez, S. J. L. P., Kumari, M., Chen, G., Hong, M.-H., Lin, Y.-S., Liu, C.-H., Ko, S.-H., Concio, C. A. P., et al. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01080-z · Cited by 129
“Owing to the demonstrated success of mRNA-LNP COVID-19 vaccines (Comirnaty ™ and Spikevax ™ ) during the pandemic, a global spotlight has been shined on the potential of the LNP platform in development of future therapeutics [161, 162].”
BackgroundKamiya, M., Matsumoto, M., Yamashita, K., Izumi, T., Kawaguchi, M., Mizukami, S., Tsurumaru, M., Mukai, H., & Kawakami, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112357 · Cited by 123
“In mRNA therapeutics, the genetic information of a therapeutic protein is administered in the form of mRNA, which is then translated into a protein in the cytoplasm to produce a pharmacological effect [1,2].”
BackgroundMartin, C. A., Marshall, C., Patel, P., Goss, C., Jenkins, D. R., Ellwood, C., Barton, L., Price, A., Brunskill, N. J., Khunti, K., et al. (2021) · doi:10.1101/2021.02.11.21251548 · Cited by 104
COVID-19 vaccine – Long term immune decline and breakthrough infections
Khoury, J., Najjar‐Debbiny, R., Hanna, A., Jabbour, A. R., Ahmad, Y. A., Saffuri, A., Abu-Sinni, M., Shkeiri, R., Elemy, A., & Hakim, F. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.038 · Cited by 111
Piernas, C., Patone, M., Astbury, N. M., Gao, M., Sheikh, A., Khunti, K., Shankar‐Hari, M., Dixon, S., Coupland, C. A. C., Aveyard, P. N., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00158-9 · Cited by 109
“17,19 In this Article, we have shown 40–74% lower odds of hospital admission or death after the second dose in all BMI categories (with slightly lower effectiveness estimates in people with underweight) and more than 90% lower odds after the third dose; however, these estimates need to be…”
One Year of Coronavirus Disease 2019 (COVID-19) in Brazil: A Political and Social Overview
Boschiero, M. N., Palamim, C. V. C., Ortega, M. M., Mauch, R. M., & Marson, F. A. L. (2021) · Annals of Global Health · doi:10.5334/aogh.3182 · Cited by 152
Mucker, E. M., Freyn, A. W., Bixler, S. L., Cizmeci, D., Atyeo, C. G., Earl, P. L., Natarajan, H., Santos, G., Frey, T. R., Levin, R. H., et al. (2024) · Cell · doi:10.1016/j.cell.2024.08.043 · Cited by 110
mRNA Covid-19 vaccines in pregnancy: A systematic review
Pratama, N. R., Wafa, I. A., Budi, D. S., Putra, M., Wardhana, M. P., & Wungu, C. D. K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0261350 · Cited by 107
“However, these adverse reactions were only transient, being resolved within a few days [25, 26].”
BackgroundTauzin, A., Gong, S. Y., Beaudoin-Bussières, G., Vézina, D., Gasser, R., Nault, L., Marchitto, L., Benlarbi, M., Chatterjee, D., Nayrac, M., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.12.004 · Cited by 116
Lessons learned from frontline skilled nursing facility staff regarding COVID ‐19 vaccine hesitancy
Berry, S. D., Johnson, K. S., Myles, L., et al. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17136 · Cited by 104
Chen, K., Fan, N., Huang, H., Jiang, X., Qin, S., Xiao, W., Zheng, Q., Zhang, Y., Duan, X., Qin, Z., et al. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202204692 · Cited by 116
The Global Impact of COVID-19 on Solid Organ Transplantation: Two Years Into a Pandemic
Nimmo, A., Gardiner, D. D., Ushiro‐Lumb, I., Ravanan, R., & Forsythe, J. L. R. (2022) · Transplantation · doi:10.1097/tp.0000000000004151 · Cited by 120
Rottenstreich, A., Zarbiv, G., Oiknine‐Djian, E., Zigron, R., Wolf, D. G., & Porat, S. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab266 · Cited by 100
Sagris, D., Papanikolaou, A., Kvernland, A., Korompoki, E., Frontera, J. A., Troxel, A. B., Gavriatopoulou, M., Milionis, H. J., Lip, G. Y. H., Michel, P., et al. (2021) · European Journal of Neurology · doi:10.1111/ene.15008 · Cited by 119
Richards, N. E., Keshavarz, B., Workman, L. J., Nelson, M. R., Platts‐Mills, T. A. E., & Wilson, J. M. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.24331 · Cited by 108
Theoretical framework for retrospective studies of the effectiveness of SARS-CoV-2 vaccines
(2021) · doi:10.1101/2021.01.21.21250258 · Cited by 103
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV
Alrubayyi, A., Gea‐Mallorquí, E., Touizer, E., Hameiri‐Bowen, D., Kopycinski, J. T., Charlton, B. G., Fisher-Pearson, N., Muir, L., Rosa, A., Roustan, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26137-7 · Cited by 115
Postvaccination COVID-19 among Healthcare Workers, Israel
Amit, S., Beni, S. A., Biber, A., Grinberg, A., Leshem, E., & Regev-Yochay, G. (2021) · Emerging Infectious Diseases · doi:10.3201/eid2704.210016 · Cited by 103
Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines
Lewnard, J. A., Patel, M. M., Jewell, N. P., Verani, J. R., Kobayashi, M., Tenforde, M. W., Dean, N. E., Cowling, B. J., & Lopman, B. A. (2021) · Epidemiology · doi:10.1097/ede.0000000000001366 · Cited by 103
Dobrowolski, C. N., Paunovska, K., Echeverri, E. S., Loughrey, D., Sanchez, A. J. D. S., Ni, H., Hatit, M. Z. C., Lokugamage, M. P., Kuzminich, Y., Peck, H. E., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01146-9 · Cited by 117
“Finally, to control for the possibility that the differential stability of PEG lipids could lead to bias in the pooled screening system, we injected three groups of mice: (1) one group of mice received an LNP with C14 PEG, then later an LNP with C18 PEG, (2) one group received an LNP with C18 PEG, then later an LNP wi…”
Association between COVID-19 outcomes and mask mandates, adherence, and attitudes
Adjodah, D., Dinakar, K., Chinazzi, M., Fraiberger, S. P., Pentland, A., Bates, S., Staller, K. D., Vespignani, A., & Bhatt, D. L. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252315 · Cited by 116
A COVID-19 Vaccine: Big Strides Come with Big Challenges
Mellet, J., & Pepper, M. S. (2021) · Vaccines · doi:10.3390/vaccines9010039 · Cited by 113
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
Grobben, M., van der Straten, K., Brouwer, P. J. M., Brinkkemper, M., Maisonnasse, P., Dereuddre‐Bosquet, N., Appelman, B., Lavell, A. H. A., van Vught, L. A., Burger, J. A., et al. (2021) · eLife · doi:10.7554/elife.70330 · Cited by 118
Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope
Dolton, G., Rius, C., Hasan, M. S., Wall, A., Szomolay, B., Behiry, E., Whalley, T., Southgate, J., Fuller, A., Morin, T., et al. (2022) · Cell · doi:10.1016/j.cell.2022.07.002 · Cited by 101
“, 2021) and a further three vaccinees who received the PfizerBioNTech BNT162b2 vaccine (Polack et al., 2020) (see materials and methods for donor and vaccination details) were stained with peptide-HLA tetramers.”
COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions
Khan, W. H., Hashmi, Z., Goel, A., Ahmad, R., Gupta, K., Khan, N., Alam, I., Ahmed, F., & Ansari, M. A. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.690621 · Cited by 117
“Storage is -70°C to -80°C; later, as an alternative, -25°C to -15°C was advised for 2 weeks (Polack et al., 2020).”
BackgroundVirus vaccines: proteins prefer prolines
Sanders, R. W., & Moore, J. P. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.002 · Cited by 102
Impact of vaccination on the COVID-19 pandemic in U.S. states
Chen, X., Huang, H., Ju, J., Sun, R., & Zhang, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-05498-z · Cited by 109
Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates
Corbett, K. S., Gagne, M., Wagner, D. A., O’ Connell, S., Narpala, S. R., Flebbe, D. R., Andrew, S. F., Davis, R. L., Flynn, B., Johnston, T. S., et al. (2021) · Science · doi:10.1126/science.abl8912 · Cited by 99
Jahn, M., Korth, J., Dorsch, O., Anastasiou, O. E., Sorge-Hädicke, B., Tyczynski, B., Gäckler, A., Witzke, O., Dittmer, U., Dolff, S., et al. (2021) · Vaccines · doi:10.3390/vaccines9040360 · Cited by 98
Accelerated waning of the humoral response to COVID-19 vaccines in obesity
van der Klaauw, A. A., Horner, E. C., Gerber, P. P., Agrawal, U., Foster, W. S., Spencer, S., Vergese, B., Smith, M., Henning, E., Ramsay, I. D., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02343-2 · Cited by 117
In vitro inactivation of SARS-CoV-2 by commonly used disinfection products and methods
Xiling, G., Chen, Y., Wang, L., Wu, X., Fan, J., Li, F., Xiaoyan, Z., Ge, Y., Chi, Y., Lunbiao, C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-82148-w · Cited by 107
Lipid in Chips: A Brief Review of Liposomes Formation by Microfluidics
Guo, Z., & Sun, J. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s331639 · Cited by 116
“The overwhelming success of lipid-based mRNA vaccines has brought a glimpse of hope in addressing the COVID-19 pandemic.(13,14) Being a safe and efficacious carrier, liposomes can protect loaded materials from external degradation and thus are being rapidly developed as a multifunctional vaccine adjuvantdelivery syste…”
BackgroundArora, G., Joshi, J., Mandal, R. S., Shrivastava, N., Virmani, R., & Sethi, T. (2021) · Pathogens · doi:10.3390/pathogens10081048 · Cited by 138
An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery
Petkar, K. C., Patil, S. M., Chavhan, S. S., Kaneko, K., Sawant, K. K., Kunda, N. K., & Saleem, I. Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040455 · Cited by 109
COVID-19 and diabetes: Association intensify risk factors for morbidity and mortality
Sharma, P., Behl, T., Sharma, N., Singh, S., Grewal, A. S., Albarrati, A., Albratty, M., Meraya, A. M., & BUNGAU, S. G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113089 · Cited by 126
COVID-19 vaccine hesitancy in underserved communities of North Carolina
Doherty, I. A., Pilkington, W. F., Brown, L., Billings, V., Hoffler, U., Paulin, L., Kimbro, K. S., Baker, B., Zhang, T., Locklear, T., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248542 · Cited by 107
“In November 2020, Moderna and Pfizer-BioNTech released their findings from randomized trials of COVID-19 vaccines, showing a remarkable 90–95% efficacy [6, 7].”
Background
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.